Infant skin care product with bionic barrier effect and preparation method thereof

Abstract

The invention relates to the technical field of cosmetics, and particularly provides a baby skin care product with a bionic barrier effect. The skin care product for infants and children is prepared from the following components in parts by weight: 1-30 parts of grease, 0-3 parts of plant extract, 0-1 part of camellia squalane, 0-2 parts of fermentation product filtrate, 0-1.5 parts of polysaccharide substances, 0.5-15 parts of an emulsifier, 0-2 parts of a thickening agent, 1-25 parts of polyhydric alcohols and the balance of water, wherein the total weight of the components is 100 parts. By optimizing the variety and dosage of the components, the components jointly take effect from different dimensions to establish a bionic barrier for the skin, and the skin care lotion shows excellent moisturizing and soothing effects, also has the characteristics of mildness, no irritation and excellent system stability, and can be used for skin care of infants and children.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, A61K8 / 92, and particularly to an infant skin care product with a biomimetic barrier function and its preparation method. Background Technology

[0002] The skin, the largest organ in the human body, serves as a vital barrier between the body and the external environment. Damage to this barrier not only leads to dryness, itching, and allergies but also triggers numerous skin-related diseases. Infant skin differs significantly from adult skin in both structure and composition. Structurally, infants have a thinner epidermis and a weaker skin barrier, making skincare products penetrate their skin more directly and easily than adults. This also results in a stronger reaction to harmful substances and sensitizing ingredients. Furthermore, infant skin contains fewer natural moisturizing components, has an incomplete sebum film, fewer beneficial bacteria, an immature immune system, and insufficient acidity and a poorer ability to regulate pH levels. These factors further contribute to the skin's susceptibility to damage from external chemicals. Therefore, skincare products with complex formulas containing alcohol or pigments, which are prone to causing allergies, should be avoided when using them on infants. Skincare products specifically formulated for infants also have higher safety requirements than those for adults.

[0003] The skin barrier, as commonly referred to in medicine, is mainly composed of two parts: the sebum film and the stratum corneum. The stratum corneum is composed of keratinocytes and intercellular lipids. By studying the composition of the natural human sebum film, and using biomimetic technology to simulate and apply components and proportions that are the same as or similar to those of the human sebum and intercellular lipids, we can develop formula ingredients that are closest to the human sebum film and can quickly integrate with the human skin's own sebum film. This can effectively establish a biomimetic skin barrier for infants and children, and improve skin repair, hydration, and other functions.

[0004] Chinese patent CN115844763A discloses a biomimetic barrier repair lotion and its preparation method. The lotion's ingredients include natural oil derivatives / ceramide lipid complexes, lipid compounds, moisturizing occlusive agents, and glycerides. However, the ceramides in it can cause skin intolerance, especially for infants and children with more delicate skin, potentially leading to redness, rashes, and other adverse reactions. Chinese patent CN116350550A discloses a moisturizing and soothing face cream and its preparation method. Its ingredients include shea butter, sodium carboxymethyl β-glucan, hydrogenated lecithin, phytosterols, sphagnum molybdenum, moisturizers, and oils. While it possesses moisturizing and soothing effects, its efficacy remains unsatisfactory.

[0005] Therefore, the present invention provides an infant skin care product with a biomimetic barrier function, which is biomimetic in terms of ingredients, structure and mechanism, replenishes the skin's missing lipids, promotes the skin barrier's self-repair, and has the functions of highly effective soothing repair, strengthening the barrier, and gentle skin care. Summary of the Invention

[0006] To address the aforementioned technical problems, this invention first provides an infant skincare product with a biomimetic barrier function; based on a total weight of 100 parts, the ingredients of the infant skincare product include: 1-30 parts of oil, 0-3 parts of plant extract, 0-1 part of camellia squalane, 0-2 parts of fermentation product filtrate, 0-1.5 parts of polysaccharides, 0.5-15 parts of emulsifier, 0-2 parts of thickener, 1-25 parts of polyol, and water to make up the balance.

[0007] Preferably, based on a total weight of 100 parts, the ingredients of the infant skin care product include: 5-25 parts of oil, 0.0001-1 part of plant extract, 0.00001-0.8 parts of camellia squalane, 0.0001-1.5 parts of fermentation product filtrate, 0.00001-1 part of polysaccharides, 1-10 parts of emulsifier, 0-1 part of thickener, 2-20 parts of polyol, and water to make up the balance.

[0008] More preferably, based on a total weight of 100 parts, the ingredients of the infant skin care product include: 10-16 parts of oil, 0.0002-0.01 parts of plant extract, 0.1-0.3 parts of camellia squalane, 0.1-0.4 parts of fermentation product filtrate, 0.00005-0.0002 parts of polysaccharides, 2-6 parts of emulsifier, 0-0.5 parts of thickener, 3.5-18 parts of polyol, and water to make up the balance.

[0009] Furthermore, the oils include, but are not limited to, at least one of the following: caprylic / capric triglyceride, coconut oil-caprylate / capric acid ester, cetyl ethylhexanoate, shea butter, sunflower seed oil, olive oil, almond oil, jojoba oil, avocado oil, shea butter, grapeseed oil, castor oil, camellia oil, snake oil, and horse oil.

[0010] Furthermore, the oil includes at least one of caprylic / capric triglyceride, cetyl ethylhexanoate, shea butter, and sunflower seed oil.

[0011] Furthermore, the oil comprises 0-10 parts caprylic / capric triglycerides, 3-15 parts cetyl ethylhexanoate, 1-6 parts shea butter, and 0.01-2 parts sunflower seed oil.

[0012] Preferably, the oil comprises 0-6 parts caprylic / capric triglyceride, 6-9 parts cetyl ethylhexanoate, 3-5 parts shea butter and 0.1-1.5 parts sunflower seed oil.

[0013] Furthermore, the plant extracts include, but are not limited to, at least one of the following: Citrus reticulata peel extract, Calendula officinalis flower extract, Olive europaea leaf extract, Echinacea purpurea extract, Centella asiatica extract, Green tea extract, and Anthemis nobilis extract.

[0014] Furthermore, the plant extracts include citrus peel extract and calendula flower extract.

[0015] Furthermore, the plant extract includes 0.0001-0.01 parts of citrus peel extract and 0.00005-0.01 parts of calendula flower extract.

[0016] Furthermore, the fermentation product filtrate includes, but is not limited to, at least one of the following: Bifida ferment filtrate, Lactobacillus / soybean milk fermentation product filtrate, Bacillus / soybean fermentation product extract, yeast / rice fermentation product filtrate, Leuconostoc / radish root fermentation product filtrate, rice fermentation product filtrate, Lactobacillus / pear juice fermentation product filtrate, and Lactobacillus / ginseng root fermentation product filtrate.

[0017] Preferably, the fermentation product filtrate includes lactobacillus / soy milk fermentation product filtrate.

[0018] The weight ratio of the citrus peel extract to the Lactobacillus / soy milk fermentation product filtrate is 0.00025-0.002:1. This application has found that the coexistence of the citrus peel extract and the Lactobacillus / soy milk fermentation product filtrate may cause system instability. This may be because the citrus peel extract contains a relatively high amount of acidic components such as polyphenols, citric acid, and malic acid. Excessive use of these acidic components can adversely affect the Lactobacillus / soy milk fermentation product filtrate, potentially leading to the precipitation or denaturation of its active ingredients. Therefore, it is necessary to strictly control the relative amounts of both.

[0019] Furthermore, the polysaccharide substances include, but are not limited to, at least one of β-glucan, carboxylated β-glucan, glycosaminoglycans, trehalose, sodium hyaluronate, and mannose.

[0020] Furthermore, the polysaccharide includes β-glucan.

[0021] Furthermore, the emulsifier is selected from at least one of hydrogenated lecithin, cetearyl alcohol, sorbitan olive oil ester, sodium stearoyl glutamate, glyceryl stearate, cetearyl alcohol olive oil ester, PEG-20 stearate, polyglycerol-2 dihydroxy stearate, and cetyl PEG / PPG-10 / 1 polydimethylsiloxane.

[0022] Furthermore, the emulsifier is cetearyl alcohol and sorbitan olive oil ester.

[0023] Furthermore, the weight ratio of cetearyl alcohol to sorbitan olive oil ester is 1-8:0.5-2, preferably 1-5:0.7-1. β-glucan has good film-forming properties, reducing skin surface moisture evaporation and allowing moisture to diffuse from the basal tissue to the stratum corneum, inducing further hydration of the stratum corneum and thus moisturizing the skin. However, β-glucan has poor water solubility and poor compatibility, easily leading to system instability when used in formulations, especially when combined with Lactobacillus / soybean fermentation product filtrate, where system stability significantly decreases. When the emulsifiers are specified as cetearyl alcohol and sorbitan olive oil ester in a weight ratio of 1-5:0.7-1, not only can the system stability problem be solved, but the moisturizing and soothing effects of the product can also be improved. This may be because both cetearyl alcohol and sorbitan olive oil ester have suitable HLB values; when used in specified amounts, their molecular chains arrange on the surface of β-glucan and undergo appropriate cross-linking, encapsulating and stabilizing the latter, promoting its uniform dispersion in the system. When both are used in excessive or insufficient amounts, the resulting emulsion structure will be affected by other polar components such as oils and plant extracts, leading to structural breakage or instability.

[0024] Furthermore, the thickener includes, but is not limited to, at least one of xanthan gum, carbomer, hydroxyethyl cellulose, gum arabic, acrylate / C10-30 alkanol acrylate crosspolymers.

[0025] Furthermore, the polyol includes, but is not limited to, at least one of propylene glycol, butanediol, glycerol, 1,2-pentanediol, hexanediol, 1,3-dibutanediol, 1,2,6-hexanetriol, and dipropylene glycol.

[0026] Furthermore, the polyol includes butanediol and glycerol.

[0027] Furthermore, the polyol comprises 0.001-8 parts of butanediol and 1-10 parts of glycerol.

[0028] Preferably, the polyol comprises 3-4 parts butanediol and 3-6 parts glycerol.

[0029] Furthermore, the ingredients of the infant skin care product also include 0-1 parts of an auxiliary agent, which includes, but is not limited to, at least one of preservatives, bactericides, UV protectants, antioxidants, and defoamers.

[0030] Furthermore, the preservatives include, but are not limited to, at least one of p-hydroxyacetophenone, phenoxyethanol, benzyl alcohol, and octanoyl hydroxamic acid.

[0031] Secondly, this application also provides a method for preparing the aforementioned biomimetic barrier-like infant skincare product, comprising the following steps: S1. Mix water, glycerin, preservative, and thickener, and heat until completely dissolved; S2. Mix the oils and emulsifiers except for sunflower seed oil, heat and stir to dissolve, then add to S1 and heat and mix. S3. Add the other raw materials to S2, mix and dissolve; S4, cooling down and discharging.

[0032] Beneficial effects (1) The components in the product of this application work together from different dimensions. Through the combined action of active substances such as oils, plant extracts, camellia squalane, fermentation product filtrate, and polysaccharides, the product simulates the skin's lipid membrane, establishes a good biomimetic skin barrier, and exhibits excellent moisturizing and soothing effects. It is also mild and non-irritating and can be used for infant skin care.

[0033] (2) This application optimizes the type and amount of emulsifier, which can further solve the problem of poor system stability caused by poor compatibility of β-glucan.

[0034] (3) This application optimizes the types and amounts of plant extracts and fermentation product filtrate to further improve the stability of the formulation system. Attached Figure Description

[0035] Appendix Figure 1 : Trend graph of cell viability changes in different groups; Appendix Figure 2 : Trend chart of changes in TNF-α inflammatory factor content in different groups. Detailed Implementation

[0036] Example Example 1 This embodiment provides an infant skincare product with a biomimetic barrier function. Based on the total weight of the ingredients, the infant skincare product comprises: 16.1 parts oil, 0.0003 parts plant extract, 0.01 parts camellia squalane, 0.1 parts fermentation product filtrate, 0.00005 parts polysaccharides, 2.15 parts emulsifier, 0.03 parts thickener, 7 parts polyol, 0.5 parts preservative, and water to make up the balance.

[0037] The oil consists of 6 parts caprylic / capric triglyceride, 6 parts cetyl ethylhexanoate, 4 parts shea butter and 0.1 parts sunflower seed oil.

[0038] The plant extracts consist of 0.0002 parts of citrus peel extract and 0.0001 parts of calendula flower extract.

[0039] The fermentation product filtrate is a lactobacillus / soy milk fermentation product filtrate.

[0040] The polysaccharide is β-glucan.

[0041] The emulsifiers are cetearyl alcohol and sorbitan olive oil ester.

[0042] The thickener is xanthan gum.

[0043] The polyol is 4 parts butanediol and 3 parts glycerol.

[0044] The preservative is p-hydroxyacetophenone.

[0045] The preparation method of the infant skincare product with biomimetic barrier function includes the following steps: S1. Mix water, glycerin, preservative, and thickener, heat to 75-85℃, stir until completely dissolved, and prepare phase A; S2. Mix all oils except sunflower seed oil and emulsifier, heat to 75-85℃ and stir to dissolve, preparing phase B. Add phase B to phase A and heat to 75-85℃, mixing until completely dissolved. S3, after mixing with the components, add it as phase C to the mixed phase of S2, and stir at 40-50℃ until completely dissolved; S4. Cool down to 35-45℃ and discharge.

[0046] Examples 2-4 Examples 2-4 all provide an infant skin care product with a biomimetic barrier function and a preparation method. The preparation method is the same as that in Example 1, and the formula information is shown in Table 1.

[0047] Table 1

[0048] In the above examples, glycerin was purchased from PROCTER & GAMBLE INTERNATIONAL OPERATIONS SASINGAPORE BRANCH, sunflower (HELIANTHUS ANNUUS) seed oil was purchased from Northstar Lipids Ltd., caprylic / capric triglycerides were purchased from BASF (China) Co., Ltd., shea butter (BUTYROSPERMUM PARKII) was purchased from Clariant Chemicals (Shanghai) Co., Ltd., cetearyl alcohol was purchased from Thai Fatty Alcohol Co., Ltd., sorbitan oleate was purchased from Proscien, cetyl ethylhexanoate was purchased from Hubei Chuyi New Materials Co., Ltd., lactobacillus / soybean fermentation product filtrate was purchased from Xianting (Guangzhou) Trading Co., Ltd., citrus (CITRUS RETICULATA) fruit extract was purchased from Shanghai Jiakai Biotechnology Co., Ltd., and calendula (CALENDULA OFFICINALIS) flower extract was purchased from Shanghai Yinong Cosmetics Technology Center. All other ingredients were commercially available.

[0049] Performance testing methods: I. Stability Testing: 1. High and low temperature test: The samples of the example were sealed and stored at -15℃, 5℃, 10℃, 15℃, 25℃, 37℃ and 45℃ for 12 weeks. Every week, the samples were taken out and placed at room temperature for 4 hours to observe whether there were any adverse phenomena such as discoloration, odor or delamination. If there were no adverse phenomena, the high and low temperature stability test was passed. 2. Cyclic Temperature Test: The sample from the example was placed in a temperature-changing chamber and stored at 25℃, -15℃, 25℃, 45℃, and 25℃ for 24 hours each, which was recorded as one cycle. After completing three cycles, the sample was taken out and placed at room temperature for 4 hours. The sample was then observed for any discoloration, odor, or stratification. If no adverse phenomena were observed, the cyclic temperature stability test was passed.

[0050] The results showed that the samples in Examples 1-2 did not exhibit discoloration, odor, or stratification after being placed at room temperature for 4 hours, and passed the high and low temperature and cyclic temperature stability tests.

[0051] II. Moisturizing Test (1) Thirty-two subjects applied the product to the inside of their arms, with each application being the size of a coin. Before measurement, the subjects cleaned their skin with water and patted it dry with lint-free absorbent paper towels. Skin moisture and transepidermal water loss were measured within 24 hours. The subjects remained relaxed and avoided touching their facial skin. The stratum corneum moisture content was measured using a Corneometer skin moisture analyzer. The specific results are shown in Table 2.

[0052] Table 2

[0053] Compared with the group that did not use moisturizing products, the stratum corneum moisture content increased significantly within 2-24 hours after using Examples 1 and 2, further demonstrating that the infant skin care products with biomimetic barrier function described in this application have obvious moisturizing effects.

[0054] (2) Thirty-two subjects applied the product to their cheeks, with each application being the size of a coin. Before measurement, the subjects cleaned their skin with water and patted it dry with lint-free absorbent paper towels. Skin moisture and transepidermal water loss were measured on days 7 and 14. The stratum corneum moisture content was measured using a Corneometer skin moisture meter, and skin moisture was measured using a skin water loss meter. The specific results are shown in Table 3.

[0055] Table 3

[0056] Compared with the group that did not use moisturizing products, the stratum corneum moisture content increased significantly at 7 and 14 days after using Examples 1 and 2, and the transepidermal water loss measurement value decreased, further demonstrating that the infant skin care products with biomimetic barrier function have obvious moisturizing effects, while also improving the skin barrier function.

[0057] III. Skin Redness Improvement Test Thirty-two subjects were selected. The product was applied to the cheeks in coin-sized amounts each time. Before measurement, subjects cleansed their skin with water and patted it dry with lint-free absorbent paper towels. Redness tests were performed on subjects using Example 1 on days 7 and 14. The a* value and percentage of red area in the skin's red zone were measured using VISIA 7-IPP and Mexameter. ® Changes in skin hemoglobin content were measured using MX18. Specific results are shown in Table 4.

[0058] Table 4

[0059] As can be seen from Table 4, the rate of change for each of the 7-day and 14-day periods using Example 1 decreased, indicating that the infant skin care product with biomimetic barrier function has a significant effect on improving skin redness.

[0060] IV. Determination of TNF-α levels (soothing effect) in mouse mononuclear macrophage leukemia cells (RAW264.7) Test method: The test was conducted in accordance with the group standard TSHRH033-2020 "Test of soothing efficacy of cosmetics - In vitro determination of TNF-α inflammatory factor content in lipopolysaccharide-induced macrophages RAW264.7 test method".

[0061] (1) RAW264.7 cytotoxicity test: The infant skincare products with biomimetic barrier function obtained in Examples 1 and 2 of this invention were formulated into eight concentration gradients, and their toxicity to mouse mononuclear macrophage leukemia cells was tested for subsequent efficacy testing. The specific experimental methods are as follows: Cell resuscitation: RAW264.7 cells were resuscitated at a rate of 8 × 10⁻⁶. 6 / bottle was inoculated into T75 bottles and incubated at 37°C in a 5% CO2 incubator for 2 days, with the medium changed daily. Plating: Culture until cell confluence reaches approximately 90%. Use a cell scraper to scrape cells from the culture flask, collect them by centrifugation, resuspend them in an appropriate amount of culture medium, and count them. Take 3.6 × 10⁶ cells from one 96-well plate. 6 Each cell was resuspended in 12 ml of basal culture medium at a concentration of 3 × 10⁶ cells / well. 4 Cells were plated in 3 replicates for each test concentration and incubated at 37°C in a 5% CO2 incubator for 24 hours.

[0062] Experimental grouping: The experiment included negative control, positive control, test samples, and blank control. Solution preparation: Prepare samples of different concentrations using complete culture medium according to the test concentration settings, filter and sterilize. The concentration gradient of the test samples is 5%, 1.667%, 0.556%, 0.185%, 0.062%, 0.021%, 0.007%, and 0.002% by volume.

[0063] Drug administration: When the cell confluence rate in the 96-well plate reached 40%-60%, drug administration was performed. The original culture medium was discarded. For the negative control, 100 μl of culture medium containing 10% dimethyl sulfoxide (DMSO) was added to each well; for the positive control, 100 μl of culture medium containing the corresponding concentration of the sample was added to each well; for the blank control, no cells were seeded, only 100 μl of culture medium was added; all groups were given LPS at a final concentration of 10 μg / ml. After drug administration, the 96-well plate was incubated at 37℃ in a 5% CO2 incubator for 20 h. Assay: Prepare 20ml MTT solution in advance: Dissolve 0.1g MTT powder in 20ml DPBS, filter to sterilize, and store in the dark to a final concentration of 5mg / ml. After 20h of cell culture, add 20μl / well of MTT solution to a 96-well plate and incubate at 37℃ in a 5% CO2 incubator for another 4h. After 4h, remove the cells, carefully aspirate the supernatant, add 150μl / well of DMSO, and mix thoroughly by pipetting. Incubate at room temperature in the dark for 30min. Use a pipette to mix the cell suspension again, and measure the absorbance of each well at OD492nm using an ELISA reader. Cell relative viability calculation: Calculated using the formula: Cell relative viability % = (Sample OD - Blank control OD) / (Negative control OD - Blank control OD) × 100% Toxicity Results: Eight drug concentrations were administered to the samples, and cytotoxicity tests were conducted on mouse mononuclear macrophage leukemia cells (RAW264.7). MTT assay results are shown in Table 5, and cell viability trends are attached. Figure 1 As shown.

[0064] Table 5

[0065] (2) Measurement of TNF-α levels (inflammatory factor) 1. Cell culture and drug administration From Table 4 and Appendix Figure 1 It is evident that the infant skincare products with biomimetic barrier function obtained in Examples 1 and 2 of this invention are non-toxic to RAW264.7 cells when used at concentrations of 5 mg / mL and below. Samples with concentrations of 5 mg / mL, 1.667 mg / mL, and 0.556 mg / mL were selected for efficacy testing. The detection method was enzyme-linked immunosorbent assay (ELISA). Specific settings are shown in Table 6.

[0066] Table 6

[0067] Cell seeding: Cells at 3 × 10⁻⁶ 4 100 μl of cells / well was seeded into a 96-well plate, with 3 replicates for each test concentration. The cells were incubated at 37°C in a 5% CO2 incubator for 24 ± 2 h.

[0068] Drug administration: After 24±2 h, the culture medium in the 96-well plate was aspirated. 200 μl of culture medium containing the test substance was added to the test substance wells, 200 μl of culture medium containing the positive control was added to the positive control wells, and 200 μl of normal complete cell culture medium was added to the negative control and blank control wells. After drug administration, the 96-well plate was pretreated at 37°C in a 5% CO2 incubator for 2 h. LPS stimulation: After the 2 h pretreatment, except for the blank control wells, LPS was added to each well to a final concentration of 10 μg / ml, and the plate was incubated at 37°C in a 5% CO2 incubator for another 24 h. Collect the supernatant: After 24 hours of incubation, collect 200 μl of cell culture supernatant from each well into a 1.5 ml sterile centrifuge tube and freeze it at -80°C for later use. 2. ELISA kit detection ELISA testing should be performed according to the instructions for use of the Mouse Tumor Necrosis Factor-α (TNF-α) Enzyme-Linked Immunosorbent Assay Kit. The specific steps are as follows: Adding standard samples: Set up standard sample wells and sample wells, and add 50 μl of standard sample of different concentrations to each standard sample well. Sample addition: Separate blank wells (blank control wells contain no sample or enzyme-labeled reagent; all other steps are the same) and sample wells for testing. First, add 40 μl of sample diluent to the sample wells on the enzyme-labeled plate. Then add 10 μl of the sample to be tested (the final sample concentration is 5 times). Add the sample to the bottom of the well of the ELISA plate, trying not to touch the well wall, and gently shake to mix. Add enzyme: Add 100 μl of HRP-Conjugate reagent to each well, except for blank wells. Incubation: After sealing the plate with sealing film, incubate at 37°C for 60 minutes.

[0069] Solution preparation: Dilute the 20x concentrated wash solution with distilled water 20 times and set aside.

[0070] Washing: Carefully peel off the sealing film, discard the liquid, shake dry, fill each well with washing solution, let stand for 30 seconds and then discard. Repeat this process 5 times, then pat dry. Color development: Add 50 μl of color developer A (Chromogen Solution A) to each well, then add 50 μl of color developer B (Chromogen Solution B), gently shake to mix, and develop at 37°C in the dark for 15 minutes. Termination: Add 50 μl of stop solution to each well to stop the reaction (the blue color will immediately turn yellow). Measurement: Zero the sample using the blank well, and measure the absorbance (OD value) of each well sequentially at a wavelength of 450 nm. The measurement should be performed within 15 minutes after adding the stop solution.

[0071] ELISA Experimental Results: The levels of the inflammatory factor TNF-α were measured according to the specific experimental method. The results are shown in Table 7, and the trend is shown in Figure 2. Details are as follows: Table 7

[0072] LPS is a major component of the cell wall of Gram-negative bacteria, released only after bacterial death and lysis or artificial destruction of the bacterial cell. Its toxic components are primarily lipid A, which can induce an immune response in mammalian cells, leading to the release of pro-inflammatory factors. (See Table 7 and appendix.) Figure 2It can be seen that when the biomimetic barrier-forming baby skincare products obtained in Examples 1 and 2 of the present invention were added to the culture medium at the test concentration to culture RAW264.7 cells, the content of the inflammatory factor TNF-α was significantly reduced when stimulated with LPS, compared with the negative control group (NC) (P<0.05). This indicates that the biomimetic barrier-forming baby skincare products obtained in Examples 1 and 2 of the present invention have an inhibitory effect on the production of the inflammatory factor TNF-α, which can be used as one of the evidences of its soothing effect.

[0073] 3. Skin occlusive patch test Human skin patch test, method of use according to: *Cosmetic Safety Technical Specifications* (2015 edition). Test purpose: To detect the potential for adverse skin reactions caused by the test substance. Subject information: 35 healthy female volunteers aged 22-46 participated in the test. Test environment: Temperature 20℃-22℃; Humidity: 40%-60%RH.

[0074] Test method: Select qualified patch testing equipment with an area not exceeding 50 mm² and a depth of about 1 mm. Using the closed patch test method, apply about 0.020-0.025 g (solid or semi-solid) or 0.020-0.025 mL (liquid) of the test substance into the small chamber of the patch testing equipment. Apply the test substance to the back of the subject with special adhesive tape. When the test sample is the original cosmetic product, the control is a blank control (without any substance). When the test product is a diluted cosmetic product, the control blank uses the diluent of the cosmetic product.

[0075] Experimental procedure: Remove the spot tester after 24 hours. If there is any remaining product, wipe it off gently with a tissue. Observe the skin reaction at 0.5 hours, 24 hours and 48 hours after removing the spot tester. Record the results according to the skin reaction grading standard in the "Cosmetic Safety Technical Specifications" (2015).

[0076] The grading criteria for skin reaction in closed patch tests are shown in Table 8.

[0077] Table 8

[0078] Result judgment criteria: Based on the cumulative calculation of test scores, the results should meet the following criteria: the number of people with grade 1 adverse skin reactions is less than or equal to 5, the number of people with grade 2 adverse skin reactions is less than or equal to 2, and the number of people with grade 3 or above adverse skin reactions is 0 (the total number of adverse skin reactions is less than or equal to 5). Table 9 summarizes the skin reaction test results of cosmetic human skin patch tests: Table 9

[0079] The results of this closed patch test showed that 0 out of 35 people experienced adverse skin reactions in the patch tests of Examples 1 and 2.

Claims

1. A baby skincare product with a biomimetic barrier function, characterized in that, Based on a total weight of 100 parts, the ingredients of the infant skin care product include: 1-30 parts oil, 0-3 parts plant extract, 0-1 part camellia squalane, 0-2 parts fermentation product filtrate, 0-1.5 parts polysaccharides, 0.5-15 parts emulsifier, 0-2 parts thickener, 1-25 parts polyol, and water to make up the balance.

2. The skincare product according to claim 1, characterized in that, The oils include at least one of the following: caprylic / capric triglyceride, coconut oil-caprylate / capric acid ester, cetyl ethylhexanoate, shea butter, sunflower seed oil, olive oil, almond oil, jojoba oil, avocado oil, shea butter, grape seed oil, castor oil, camellia oil, snake oil, and horse oil.

3. The skincare product according to claim 2, characterized in that, The oil comprises 0-10 parts caprylic / capric triglycerides, 3-15 parts cetyl ethylhexanoate, 1-6 parts shea butter and 0.01-2 parts sunflower seed oil.

4. The skincare product according to claim 3, characterized in that, The plant extracts include at least one of the following: citrus peel extract, calendula flower extract, olive leaf extract, echinacea extract, centella asiatica extract, green tea extract, and chamomile extract.

5. The skincare product according to claim 4, characterized in that, The plant extracts include citrus peel extract and calendula flower extract.

6. The skincare product according to claim 4, characterized in that, The fermentation product filtrate includes at least one of the following: Bifida ferment filtrate, Lactobacillus / soy milk fermentation product filtrate, Bacillus / soybean fermentation product extract, yeast / rice fermentation product filtrate, Leuconostoc / radish root fermentation product filtrate, rice fermentation product filtrate, Lactobacillus / pear juice fermentation product filtrate, and Lactobacillus / ginseng root fermentation product filtrate.

7. The skincare product according to claim 6, characterized in that, The weight ratio of the citrus peel extract to the lactobacillus / soy milk fermentation product filtrate is 0.00025-0.002:

1.

8. The skincare product according to claim 7, characterized in that, The emulsifier is selected from at least one of hydrogenated lecithin, cetearyl alcohol, sorbitan olive oil ester, sodium stearoyl glutamate, glyceryl stearate, cetearyl alcohol olive oil ester, PEG-20 stearate, polyglycerol-2 dihydroxy stearate, and cetyl PEG / PPG-10 / 1 polydimethylsiloxane.

9. The skincare product according to claim 8, characterized in that, The weight ratio of cetearyl alcohol and sorbitan olive oil ester is 1-8:0.5-2, preferably 1-5:0.7-1.

10. A method for preparing a skincare product according to any one of claims 1-9, characterized in that, Includes the following steps: S1. Mix water, glycerin, preservative, and thickener, and heat until completely dissolved; S2. Mix the oils and emulsifiers except for sunflower seed oil, heat and stir to dissolve, then add to S1 and heat and mix. S3. Add the other raw materials to S2, mix and dissolve; S4, cooling down and discharging.

Images